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Patient-Specific Naturally Gene-Reverted Induced
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Jakub Tolar1,2, John A. McGrath3, Lily Xia1, Megan J. Riddle1, Chris J. Lees1, Cindy Eide1, Douglas R. Keene4,
Lu Liu3, Mark J. Osborn1, Troy C. Lund1, Bruce R. Blazar1 and John E. Wagner1
Spontaneous reversion of disease-causing mutations has been observed in some genetic disorders. In our clinical
observations of severe generalized recessive dystrophic epidermolysis bullosa (RDEB), a currently incurable
blistering genodermatosis caused by loss-of-function mutations in COL7A1 that results in a deficit of type VII
collagen (C7), we have observed patches of healthy-appearing skin on some individuals. When biopsied, this skin
revealed somatic mosaicism resulting in the self-correction of C7 deficiency. We believe this source of cells could
represent an opportunity for translational ‘natural’ gene therapy. We show that revertant RDEB keratinocytes
expressing functional C7 can be reprogrammed into induced pluripotent stem cells (iPSCs) and that
self-corrected RDEB iPSCs can be induced to differentiate into either epidermal or hematopoietic cell
populations. Our results give proof-of-principle that an inexhaustible supply of functional patient-specific
revertant cells can be obtained—potentially relevant to local wound therapy and systemic hematopoietic cell
transplantation. This technology may also avoid some of the major limitations of other cell therapy strategies, e.g.,
immune rejection and insertional mutagenesis, which are associated with viral- and nonviral-mediated gene
therapy. We believe this approach should be the starting point for autologous cellular therapies using ‘natural’
gene therapy in RDEB and other diseases.
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INTRODUCTION
Cells originating from the bone marrow (BM) maintain func-
tional integrity of multiple parenchymal tissues, typically as
cells involved in local immunity (Kupper and Fuhlbrigge,
2004). In addition, BM cells have been shown to aid in tissue
repair (Badiavas et al., 2003), and this concept has been
applied therapeutically in BM transplantation for the inherited
blistering skin disorder, recessive dystrophic epidermolysis
bullosa (RDEB; Fine et al., 2008; Tolar et al., 2009; Wagner
et al., 2010). RDEB is caused by loss-of-function mutations in
the collagen type VII gene COL7A1 (Bruckner-Tuderman,
2010). First in animal models (Chino et al., 2008; Tolar
et al., 2009) and later in a clinical trial (Wagner et al.,
2010), BM and cord blood cells from healthy donors were
shown to home to injured mucocutaneous membranes in
RDEB patients and mediate wound healing, with histo-
logic evidence for cross-correction of the type VII collagen
(C7) deficiency in the skin. However, hematopoietic
cell transplantation (HCT) is not available for everyone,
either because the patient does not have a suitably human
leukocyte antigen-matched donor or is not sufficiently affected
to justify the risks of the transplant procedure. Physical injury
(e.g., renal and pulmonary toxicity) and immune injury (e.g.,
profound immunodeficiency) are common after allogeneic
HCT. These complications can limit the clinical application of
transplant therapy to RDEB and other extracellular matrix
disorders.
Autologous HCT, however, would be expected to have
significantly fewer risks. Gene correction of autologous cells
would be a necessary prerequisite for such therapy. Because
of the large size of the COL7A1 gene and the possibility that
both viral- and nonviral-mediated gene therapies result in
unwanted off-target side effects, traditional gene therapy may
be neither optimal nor desirable. Fortunately, nature provides
an alternative. Some RDEB individuals develop skin patches
that never blister because of a spontaneous COL7A1 gene
correction in a subpopulation of keratinocytes (not fibroblasts;
Almaani et al., 2010; Pasmooij et al., 2010; Lai-Cheong et al.,
2011). Such ‘natural’ gene therapy can result in the normal
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expression of C7 protein in skin. We hypothesized that if these
revertant keratinocytes could be expanded, they might
represent an ideal cellular substrate for autologous cell
therapy, with no need for gene correction and the additional
risk of genotoxicity that can be associated with viral and
nonviral gene-delivery methods (Hacein-Bey-Abina et al.,
2003; Howe et al., 2008). The mosaic skin cells can be
used for local applications to skin wounds, but there are
significant limitations to the benefits for the patient: (1) highly
proliferative skin cells appear to be depleted from mutant and
mosaic skin of epidermolysis bullosa (EB) individuals (De Luca
et al., 2009; Petrova et al., 2010); (2) even if such cells were
isolated, only a finite number of passages, i.e., a limited
number of cells, can be derived from them; and (3) mucocu-
taneous wounds are often not readily accessible, and thus
local wound treatment cannot provide the desired universal
therapy. To solve these problems, we hypothesized that the
revertant keratinocytes could be induced to pluripotency, and
that both hematopoietic and nonhematopoietic cells of
various lineages could be derived from them for a life-long
supply of patient-specific cells for both systemic and local
treatment of RDEB.
Here we show that induced pluripotent stem cells (iPSCs)
can be derived from both mutant and revertant keratinocytes
of the same RDEB individual. Both stratified skin epithelium
and cells with hematopoietic characteristics were differen-
tiated from these iPSC populations. Thus, in principle, the
benefits of ‘natural’ gene therapy can be amplified by cellular
reprogramming for future applications in autologous cell
therapy in RDEB and other skin extracellular matrix disorders.
RESULTS
Spontaneous clinicopathologic reversion of a patch of RDEB skin
The subject, a 10-year-old boy with generalized severe RDEB,
had involvement of the oral and esophageal mucosa and a
large cutaneous surface area that manifested as blisters and
erosions (Figure 1a). Strikingly, a 7 11-cm patch of skin
between the umbilicus and the pubis was entirely unaffected
(Figure 1b) and had never blistered since birth. In contrast
to immunofluorescence studies for expression of C7 in which
no signal was detected at the dermal-epidermal junction
(Figure 1c), strong continuous C7 staining was observed in a
skin specimen obtained from the unaffected area (Figure 1d).
In support of these data, keratinocytes isolated from this
unaffected skin expressed C7 (Supplementary Figure S1
online) and, when examined by transmission electron
microscopy, homotrimers of C7 (termed anchoring fibrils)
and prominent C7 immunolabeling adjacent to the basement
membrane were present in the healthy-appearing skin
(Supplementary Figure S1 online), whereas they were absent
in the blistered skin (data not shown). These clinical, bio-
chemical, and ultrastructural observations were consistent
with the possibility that a spontaneous correction of one of
the mutations in the COL7A1 had occurred.
To investigate the etiology of this apparent somatic mosai-
cism, we performed allele-specific sequencing. Constitution-
ally, we found the boy to be a compound heterozygote for two
loss-of-function mutations in COL7A1, a paternal frameshift
mutation c. 3840delC (p.Thr1280Thrfs*44) and a maternal
acceptor splice site mutation g.6751-2A4G (IVS85-2A4G).
Therefore, one truncated (paternal) and one mis-spliced
(maternal) COL7A1 mRNA products were generated. Direct
complementary DNA sequencing revealed that the paternal c.
3840delC COL7A1 frameshift mutation was present in cells
derived from blistered skin and from nonblistered (mosaic)
skin (data not shown). However, complementary DNA PCR of
the COL7A1 region surrounding the maternal g.6751-2A4G
mutation located in intron 85 indicated skipping of exon 86
and generation of a presumably functional COL7A1 transcript
(Supplementary Figure S2 online).
Revertant skin cells can be reprogrammed to iPSCs
Restoration of normal biochemical (Figure 1 and
Supplementary Figure S1 online) and ultrastructural phenotype
(Supplementary Figure S1 online) immediately suggested the
possibility of a treatment strategy by using the patient-specific
self-corrected cells. To provide preclinical evidence that such
cells can be amplified into clinically meaningful numbers and
phenotypes, we generated iPSCs from the COL7A1 revertant
cells and, as a control, the COL7A1 mutant skin cells from the
same individual. Following the well-established technology
for the development of iPSC-based disease models (Park et al.,
2008; Bilousova et al., 2011; Itoh et al., 2011), we transduced
COL7A1 revertant skin keratinocytes with OCT4-, SOX2-,
KLF4-, and c-MYC-encoding retroviral vectors. After 3–6
weeks, 2–3 colonies of iPSCs per 100,000 primary skin cells
emerged from the monolayer of supportive stromal cells.
When compared with parental skin cells, iPSCs showed
persistent mRNA expression of the OCT4 and SOX2 used for
reprogramming, as well as other genes associated with
pluripotency in iPSCs (such as NANOG, LIN28, and
DNMT3b; Figure 2a). As would be expected to occur in
Figure 1. Mosaicism in recessive dystrophic epidermolysis bullosa (RDEB).
(a) Blistered skin in a boy with generalized severe RDEB. Arrow points to the
area seen in b. (b) Small patch of unaffected skin in the pubic area (arrows).
(c) Blistered skin with no detectable expression of type VII collagen.
(d) Nonblistered, pubic-area skin from the same individual with strong
continuous linear labeling of type VII collagen (red) at the dermal-epidermal
junction. Nuclei are stained with 4,6-diamidino-2-phenylindole (DAPI; blue).
Bar¼50mm.
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wild-type (WT) iPSCs, there was transient mRNA expression of
c-MYC and KLF4, also used to mediate reprogramming
(Figure 2a). Also as expected, the exogenous OCT4 and
SOX2 transgenes had been silenced in the iPSCs (Supple-
mentary Figure S3a and b online). Consistent with their
acquired immaturity, the iPSCs expressed protein markers
characteristic of fully reprogrammed iPSCs: TRA-1-81, stage-
specific embryonic antigens 3 and 4, OCT4, and NANOG
(Figure 2b and c). As these reprogramming factors are believed
to activate a network of transcriptional factors, which in turn
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induce epigenetic changes (Freberg et al., 2007; Aasen et al.,
2008; Okita et al., 2008), we used bisulfite sequencing to
confirm the methylation status of OCT4 and NANOG
promoters in the iPSCs. A methylated pattern is indicative of
gene silencing, whereas an unmethylated pattern indicates the
potential for robust gene expression. Individual colonies of
cells from mutant iPSCs and revertant iPSCs showed a
methylation pattern characteristic of iPSCs, in which OCT4
and NANOG promoter sequences are unmethylated. In
contrast, parental skin cells had the expected pattern of
partially methylated sequences (Figure 3a–d).
Both mutant iPSCs and revertant iPSCs had normal karyo-
types as determined by high-resolution chromosomal G-band-
ing (Supplementary Figure S4 online). To verify that the iPSCs
originated from patient-derived primary cells, we performed
PCR reaction of variable number tandem repeats on genomic
DNA isolated from both mutant and revertant iPSCs (data not
shown). To provide further evidence of the identity of iPSCs at
a functional level, iPSCs were injected intramuscularly into
immune-deficient mice. Within 6–8 weeks, well-differentiated
cystic teratomas were observed, confirming the phenotype-
defining ability of iPSCs to differentiate in vivo into a wide
array of cell lineages encompassing endodermal, mesodermal,
and ectodermal origins (Figure 4). Collectively, the transcrip-
tion profile, cellular phenotype, and in vivo behavior of
the iPSCs were consistent with the morphological and pheno-
typical gain of cellular pluripotency.
Two cell types are most relevant for the preclinical modeling
of revertant iPSC application for a skin extracellular matrix
disorder such as RDEB: (1) hematopoietic cells with the
potential to be used in the future for autologous HCT as
efficacious as allogeneic HCT but with less toxicity and (2) skin
cells to be used in the local therapy of individual wounds,
analogous to the skin injections of fibroblasts and mesenchy-
mal stromal cells from unrelated donors that are already used
in subjects with RDEB (Wong et al., 2008; Conget et al., 2010).
Blood cells and hematopoietic colonies can be derived from
revertant iPSCs
To test the blood-forming potential of the revertant iPSCs, we
activated hematopoietic cell fate commitment in iPSCs using
the formation of embryoid bodies and differentiation in
medium containing human hematopoietic growth factors:
stem cell factor, Flt3 ligand, IL-3, IL-6, granulocyte colony-
stimulating factor, and bone morphogenetic protein 4 (Tolar
et al., 2011b, c). Consistent with the conversion of iPSCs into
hematopoietic progenitor cells, approximately one-third of the
cells expressed an antigen found on hematopoietic stem cells:
CD34 (Figure 5a and b). To further define the commitment of
these cells expressing hematopoietic surface antigens to
hematopoietic lineage, the capacity of hematopoietic progeni-
tors from WT, mutant, and revertant iPSCs to function as
colony-forming units was quantified using the colony-forma-
tion assay (mean±SEM; WT, 52±22 colonies; mutant RDEB,
174±15 colonies; and revertant RDEB, 100±17 colonies).
Consistent with the pattern we described previously for gene-
corrected hematopoietic cells derived from iPSCs (Tolar et al.,
2011b, c), the differences between WT and mutant cells, and
revertant and mutant cells, were statistically significant
(Po0.05), whereas the difference between WT and revertant
cells was not (Figure 5c). We speculate that increased seeding
capacity of the cells in semisolid medium is due to a
combination of higher proliferation rate (as evidenced by
higher number of hematopoietic cells expressing stem cell
marker CD34) and decreased connectivity among mutant cells
owing to the lack of C7 in the extracellular matrix within the
cellular colony of cells in semisolid medium.
Skin cells and three-dimensional skin can be derived from
revertant iPSCs
To demonstrate that, in principle, revertant iPSCs can be used
as a resource for the unlimited production of disease-free,
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Figure 3. Epigenetic signature of recessive dystrophic epidermolysis bullosa
(RDEB) induced pluripotent stem cells (iPSCs). (a) A partially methylated
pattern indicative of gene silencing of OCT4 and NANOG promoter sequences
in mutant primary cells. (b) An unmethylated pattern in mutant iPSCs
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clinically relevant cells, we derived keratinocytes from them,
as described (Tolar et al., 2011b, 2012), and showed that they
expressed C7 (Figure 6a). To further confirm functionality of
the revertant iPSC-derived keratinocytes, we derived three-
dimensional skin with epidermis-like layers of keratinocytes
(expressing keratin 5) and a layer of C7 at the site analogous to
the basement membrane in normal skin (Figure 6b) and
comparable to the C7 expression in the revertant skin of this
individual (Figure 1d).
In summary, these data show that iPSCs can be generated
from revertant RDEB skin cells and that such iPSCs can
differentiate into cells of hematopoietic and epidermal
lineages.
DISCUSSION
We show that somatic mosaicism can form a platform for
clinical intervention in RDEB and can be viewed as sponta-
neous ‘natural’ gene therapy of this severe genodermatosis.
Reversion in COL7A1 presumably occurs in a single skin cell,
and selection of the new cellular phenotype then leads to
growth expansion of progeny cells with the functional
COL7A1 allele. Such cellular cloning in an EB individual,
however, typically results in correction of only a small area of
the skin and may not substantively increase the quality of life.
Therefore, to make the available number of genetically distinct
self-corrected skin cells clinically meaningful, we hypothe-
sized that the mosaic cells could be amplified by reprogram-
ming into pluripotency. Here we show that karyotypically
stable and functional iPSCs can be derived from revertant
RDEB skin cells. Although skin in the mosaic patch did not
blister and appeared clinically normal (Figure 1), in principle,
reversions of COL7A1 mutations could result in hypomorphic
rather than fully functional C7. Nevertheless, we anticipate
that iPSC-derived cells can be of major benefit to many people
with RDEB in both local wound therapy (when differentiated
to keratinocytes or fibroblasts) and systemic therapy (when
differentiated to hematopoietic cells).
iPSCs are engineered stem cells that have the potential to
develop into any other cell type in the body, much like
embryonic stem cells. As there are fewer ethical limitations
associated with human iPSCs than human embryonic stem
cells, iPSCs have become a popular tool for the investigation
of tissue formation in health and disease, early stages of
development, and drug intervention strategies (Taapken et al.,
2011; Zhao et al., 2011; Zhu et al., 2011), all relevant to EB
biology and treatment. Critical iPSC issues regarding transgene
integration-free reprogramming, genomic fidelity, and
transplantability (Anokye-Danso et al., 2011; Chen et al.,
2011; Choi et al., 2011; Okita et al., 2011) are simultaneously
being investigated in an effort to develop genomically stable,
personalized iPSC-derived cells that are free of contamination
with undifferentiated cells and less susceptible to immune
rejection after transplantation. Critically, the data from iPSC
biology can make possible the previously impossible advances
in cell therapy tailored to specific clinical needs, such as
expansion of disease-free cells from RDEB individuals with
somatic mosaicism.
Any genetic disease can, in theory, be spontaneously
corrected by a gene conversion, a compensatory mutation in
cis, or by an intragenic crossover between maternal and
paternal alleles with two different mutations in the same gene
(Hirschhorn, 2003). Functional restoration of revertant cells
has been reported in patients with a number of genetic
diseases, such as EB, hereditary tyrosinemia type I, the BM
failure syndromes Fanconi anemia and dyskeratosis congenita,
and primary immunodeficiencies such as Wiskott-Aldrich
syndrome, Bloom syndrome, X-linked severe combined
immunodeficiency, and adenine deaminase-deficient severe
combined immunodeficiency (Ellis et al., 1995; Hirschhorn
et al., 1996; Stephan et al., 1996; Jonkman et al., 1997; Lo Ten
Foe et al., 1997; Ariga et al., 1998; Darling et al., 1999;
Gregory et al., 2001; Gross et al., 2002; Schuilenga-Hut et al.,
2002). Although the likelihood of reversion is presumably
related to genetic instability in disorders of DNA repair, such
as Fanconi anemia, ataxia telangiectasia, and Bloom
syndrome, to our knowledge no such reason for increased
opportunity for correction has been described for RDEB.
Nevertheless, it is conceivable that the highly repetitive
COL7A1 sequence and open chromatin structure during
early stages of skin development combine to form a
permissive environment for slipped DNA strand mispairing
and other mechanisms underlying the somatic mosaicism. As
these circumstances can equally well explain the introduction
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of pathogenic mutations in the first place, the favorable
effect of the self-correcting mutation presumably becomes
clinically obvious because of a selective growth advantage of
revertant cells in vivo. Therefore, it is likely that
additional factors, such as early events associated with
severe cellular stress, e.g., p53-dependent apoptosis
(Liu et al., 2003), could contribute to the selection of these
prenatal molecular events. At present, however, the cause and
the time required for such selection remains unknown
(Pasmooij et al., 2012).
The prognostic consequences of reversion may be difficult
to predict, as they depend not only on the relative number of
self-corrected cells but also on how relevant the cell pheno-
type is to the primary disease. Both of these characteristics in
turn depend on the proliferation potential (i.e., pluripotenti-
ality, ‘stemness’; Gregory et al., 2001; Mankad et al., 2006)
and location of the revertant cells. Relevant to RDEB, even a
less-than-complete level of mosaicism can be beneficial, as
only 30–40% of the WT level of C7 expression may be
necessary to prevent blistering (Fritsch et al., 2008; Kern
et al., 2009). Furthermore, the mutation leading to restoration
of function need not restore the original DNA sequence.
Owing to changes in post-translational modifications, the
stability and ability to secrete the protein coded by the allele
that has been repaired with a second site mutation may be
only partially functional and still translate into a clinically
meaningful change. Critically, a patient-specific combination
of quantitative (the absolute level of C7 production) and
qualitative (the ability of the partially functional C7 to
polymerize into anchoring fibrils) factors will determine the
prognostic consequences of somatic mosaicism in individuals
with RDEB.
The somatic mosaicism in EB is visible, and thus it is
understandable to assume that only the healthy-appearing skin
area is its full representation, with the rest of the mucocuta-
neous membranes carrying the biallelic germline pathogenic
mutations and not being corrected by the reversion event. As
the frequency of somatic mosaicism is largely unknown,
however, subclinical micromosaicism may exist in the skin,
which could, in principle, contribute to the imperfect
genotype–phenotype correlation in the EB individuals.
Furthermore, as hematogenous cells from BM integrate into
injured skin (Chino et al., 2008; Fu and Sun, 2009; Wagner
et al., 2010; Tolar et al., 2011b), and as the reversions during
early prenatal development have been described in
hematologic genetic disorders (described above), it is
possible that reversion in a multilineage BM cell can lead to
repopulation of large areas of skin with C7-producing cells.
This in turn can translate into long-term, albeit partial,
restoration in skin integrity, and can provide another
explanation for the phenotypical heterogeneity in various
forms of EB (Fine, 2010; Kiritsi et al., 2011).
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In summary, we show that iPSCs can be derived from
mutant and revertant skin from an RDEB individual with
somatic mosaicism in COL7A1. From the perspective of skin
pathology, this may provide a system to study mosaicism in a
mechanistic manner. From the perspective of stem cell gene
therapy in general, this approach may provide solutions to one
major safety issue (the genotoxicity associated with viral-
mediated gene therapy) and to one major technical roadblock
in the development of technology that can rebuild injured skin
(the paucity of adult stem cells in RDEB skin that has been
exhausted by years of nonhealing tissue repair). Although this
proof of concept supports the possibility of generating a
limitless supply of patient-specific C7-producing cells for
autologous cell therapy with self-corrected cells to ameliorate
RDEB, the safety guidelines for such stem cell gene therapy
will undoubtedly continue to be refined to deliver the benefits
of this approach correctly, safely, and reliably. As further
advances in RDEB research (Uitto et al., 2010), as well as
cellular reprogramming, differentiation, and transplantation
occur, each will be rapidly incorporated into a clinically
meaningful design for the personalized cellular therapy of
RDEB, one of the most painful and desperate of human
conditions (Tolar et al., 2011a).
MATERIALS AND METHODS
Skin cells
After obtaining written, informed consent as approved by the
Institutional Review Board of the Human Subjects Committee at the
University of Minnesota, skin biopsies were collected from a healthy
volunteer and from an individual with RDEB. All procedures adhered
to the Declaration of Helsinki Principles. Skin was cut into 2 2 mm
pieces. The dermis was peeled from the epidermis, placed in six-well
plates with each well containing 2 ml of medium, and immobilized
under a sterile coverslip. Human fibroblast medium consisted of
DMEM (Invitrogen, Grand Island, NY), 10% fetal bovine serum
(Invitrogen), and penicillin/streptomycin (Invitrogen). The medium
was changed every 2 days until the culture became 90% confluent, at
which point the cells were lifted using 0.25% trypsin EDTA and
serially replated. Human keratinocytes were grown in EpiLife medium
(Cascade Biologics, Portland, OR) supplemented with 0.06 mM
Ca2þ , 1% EpiLife-defined growth supplement, and 1% penicillin/
streptomycin (Invitrogen). Cultures were maintained at 37 1C in a
humidified atmosphere of 5% CO2 and 95% air.
Histological evaluations
Skin biopsies were frozen in optimal cutting temperature (Sakura
Finetek USA, Torrance, CA) and cut at 6mm on a cryostat. Sections
were fixed in room-temperature acetone for 5 minutes, followed by
blocking with 10% normal donkey serum for 1 hour (Jackson Immu-
noresearch, West Grove, PA). Primary antibody specific for C7 (1:250,
lot 01591 30625, immunogen residues 952–1162, from BD Bio-
sciences, San Jose, CA) was added for 1 hour, washed, and then
secondary antibody donkey anti-mouse Cy3 (1:500; Jackson Immu-
noresearch) was applied for 1 hour. Slides were washed, coverslipped
with hard set 4,6-diamidino-2-phenylindole (Vector Labs, Burlingame,
CA), and examined by confocal fluorescence microscopy (Olympus
BX61; Olympus Optical, Tokyo, Japan). Ultrastructural skin examina-
tion was performed as described (Wagner et al., 2010).
Cellular reprogramming
About 50,000 keratinocytes were seeded per well in a six-well plate
and infected with a 1:1:1:1 mix of retroviral supernatants of pMIG
containing OCT4, SOX2, KLF4, and c-MYC in the presence of
5mg ml 1 protamine sulfate. Infection consisted of a 45-minute spin
infection at 1,800 r.p.m. at room temperature, after which the super-
natants were left in contact with the cells for 24 hours at 37 1C and 5%
CO2. The next day, cells were spin-infected a second time by using the
same procedure. Five days after beginning the last round of infection,
cells were trypsinized and seeded onto feeder layers of irradiated CF1
murine embryonic fibroblasts in the same culture medium. After
24 hours, the medium was changed to human embryonic stem cell
medium, consisting of DMEM/F12 (Invitrogen) supplemented with
10% KO-Serum Replacement (Invitrogen), 2 mM GlutaMAX (Invitro-
gen), 50mM 2-mercaptoethanol (Invitrogen), 1 nonessential amino
acids (Invitrogen), 50 U ml 1 penicillin, 50 mg ml 1 streptomycin, and
10 ng ml 1 basic fibroblast growth factor (R&D Systems, Minneapolis,
MN). Cultures were maintained at 37 1C and 5% CO2, with daily
medium changes. Colonies were picked on the basis of morphology
20–30 days after the initial transduction.
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Figure 6. Epidermal differentiation of recessive dystrophic epidermolysis
bullosa (RDEB) induced pluripotent stem cells (iPSCs). (a) Keratinocytes
derived from revertant iPSCs express type VII collagen (red). Original
magnification  40. (b) Three-dimensional skin from teratoma (Figure 4b)
with epidermis-like layers of keratin 5–expressing keratinocytes (green) and
linear type VII collagen immunoreactivity at the dermal-epidermal junction
(red). Nuclei are stained with 4,6-diamidino-2-phenylindole (DAPI; blue).
Bar¼50mm.
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Evaluations of iPSCs
Genome analyses (nucleic acid isolation, quantitative PCRs,
bisulfite sequencing, and karyotypes) were performed with stan-
dard techniques as described (Supplementary Methods online and
Tolar et al., 2012). For live staining, the TRA-1-60 antibody
(1:400, Millipore, Billerica, MA) and secondary antibody Alexa
488-conjugated anti-mouse IgM (1:400, Invitrogen) were diluted
in human embryonic stem cell medium and added into the culture
plate. The plate was incubated at 37 1C for 1 hour before the
medium was changed to fresh conditioned medium. TRA-1-60þ
colonies were identified under a fluorescence microscope. For
immunofluorescence evaluations, iPSCs grown on feeder cells in
chamber slides were fixed with 4% paraformaldehyde for 15 min-
utes. If nuclear permeation was needed, cells were treated with
0.2% TritonX (Sigma-Aldrich, St Louis, MO) in phosphate-buffered
saline for 30 minutes. Cell preparations were blocked in 3% BSA in
phosphate-buffered saline for 2 hours, and incubated with primary
antibody overnight at 4 1C. The following antibodies were used: TRA-
1-60 (clone MAB4360, 1:400), TRA-1-81 (clone MAB4381, 1:400),
SSEA4 (clone MAB4304, 1:100), and SSEA3 (clone MAB-4303,
1:100) from Millipore; NANOG (clone EB06860, 1:100) from Everest
Biotech, Upper Heyford, UK; OCT3/4 (clone AB27985, 1:200) from
ABCAM, Cambridge, MA; and SOX2 (clone 630802, 1:500) from
Biolegend, San Diego, CA. All secondary antibodies used were Alexa
Fluor Series from Invitrogen (all 1:500), and they were incubated
for 1 hour at room temperature. Images were taken using a confocal
microscope (Olympus BX61). Direct alkaline phosphatase activity
was analyzed using the Alkaline Phosphatase Staining Kit according
to the manufacturer’s recommendations (Millipore). For teratoma
formation, young adult NOG mice were injected with one million
cells resuspended in a mixture of DMEM/F12 Matrigel (BD
Biosciences) and type IV collagen (ratio 2:1:1, 40ml per mouse) into
the right quadriceps muscle. Tumors were collected in 3–8 weeks
and cryopreserved at  80 1C in optimal cutting temperature medium
(Sakura Finetek USA).
Hematopoietic and epidermal differentiation of iPSCs
For hematopoietic differentiation, embryoid bodies were produced by
confluent cultures, collected by enzymatic dissociation (Accutase,
Invitrogen) to single cells, and added to AggreWell plates (StemCell
Technologies, Vancouver, BC, Canada). According to the manufac-
turer’s recommendations, cells were differentiated for 1 day in basic
embryoid body medium, containing knockout DMEM (Invitrogen)
supplemented with 20% fetal calf serum, 0.1 mM nonessential amino
acids (Invitrogen), 0.1 mM b-mercaptoethanol (Sigma-Aldrich), 1 mM
L-glutamine (Invitrogen), 50mg ml 1 ascorbic acid (Sigma-Aldrich),
and 200mg ml 1 human holo-transferrin (Sigma-Aldrich). After
24 hours, embryoid bodies were transferred to low-attachment dishes,
and human stem cell factor (300 ng ml 1), human Flt3 ligand
(300 ng ml 1), human IL-3 (10 ng ml 1), human IL-6 (10 ng ml 1),
granulocyte colony-stimulating factor (50 ng ml 1), and human bone
morphogenetic protein 4 (50 ng ml 1) were added to the cultures (all
cytokines from R&D Systems). At the time of analysis, embryoid
bodies were collected and dissociated into single cells. Hematopoie-
tic cells were characterized by flow cytometry analysis for CD34
expression and by colony-forming unit assay as described (Tolar
et al., 2011b). For epidermal differentiation, keratinocytes were
derived from iPSCs as described (Tolar et al., 2012).
Colony-forming assay
The hematopoietic cells derived from iPSCs were counted by using a
hemocytometer and were resuspended at a maximum concentration
of 25,000 cells per ml in Iscove’s modified Dulbecco’s medium and
2% fetal bovine serum. A volume of 400ml of the cell suspension was
added to 4-ml aliquots of Human Methylcellulose Enriched Medium
(catalog number HSC005, R&D Systems). The suspension was equally
divided and placed in three 35-mm tissue culture plates and
incubated at 37 1C in 5% CO2 for 14 days. The plates were examined
under a microscope, and colony-forming unit (granulocyte-monocyte
progenitor cells) and burst-forming unit (erythroid progenitor cells)
colonies containing 450 cells were scored as colonies.
Data analysis
Differences between measurements were evaluated with Student’s
t-test, with P-valueso0.05 considered significant.
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